Hikma and Celltrion have struck an exclusive licensing agreement that will see the firms add another biosimilar to the pair’s collaboration in the Middle East and North Africa, which already sees Hikma market a host of Celltrion products in the region.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?